Soraya Bekkali

Vedere Bio, Inc. develops cutting-edge gene therapy products to restore functional vision to patients who have suffered vision loss. The company was founded in June 2019 and is headquartered in Cambridge, MA.

LabCentral, Inc. provides grant making services for bio-tech companies. The firm?s services include maintenance of permits for all lab operations, mandatory EHS training and compliance for all lab users, maintenance of equipment and technical support, CRO support available on-site (FTE basis), cleaning and waste removal. The company was founded by Timothy D. Rowe, Johannes Fruehauf, Peter D. Parker in September 2012 and is headquartered in Cambridge, MA.

Northwestern University is a private institution founded in 1851 to serve the Northwest Territory, an area that now includes the states of Ohio, Indiana, Illinois, Michigan, Wisconsin and parts of Minnesota. Northwestern has three campuses

BioInnovation Management LLC (Bioinnovation Management) is a venture capital firm founded in 2009 by Peter D Parker and Susie T Harborth. The firm is headquartered in Cambridge, Massachusetts.

Jupiter Bioventures LLC is a biotech company studio that aims to create innovative companies and develop groundbreaking medicines. The company is based in Wilmington, DE. The CEOs of the company are Nathaniel E. David, Norman E. Sharpless.

Arclight Therapeutics LLC is an American bio-pharmaceutical company founded by Steven Tregay. The company operates in the field of developing and producing pharmaceutical products.

Eikonizo Therapeutics, Inc. provides healthcare services. The company was founded in 2017 and is headquartered in Beverly, MA.

Compass Therapeutics LLC operates as a healthcare industry focusing on biotechnology. It offers drug discovery, development, biologics, oncology and immuno-oncology. The company was founded by Errik B. Anderson and Thomas J. Schuetz in 2014 and is headquartered in Cambridge, MA.

Cequent Pharmaceuticals, Inc. developed therapeutics and pharmaceuticals. The company was founded in 2006 and was headquartered in Cambridge, MA.

Thermalin, Inc. engages in the development of insulin products for patients with diabetes. It offers stabilized, ultra-rapid, and highly concentrated; no refrigeration basal and mix; glucose-responsive smart basal; and StampPump insulins. The company was founded by Michael A. Weiss, Bruce H. Frank, and Richard Berenson in 2010 and is headquartered in Cleveland, OH.

Novartis Option Fund invests in early stage biotech start-ups with innovative technology platform enabling the development of novel programs and technologies. The individual investment is coupled with an option to a specific therapeutic program. The fund targets two or more investments per year which would be financed in a syndicate with other VCs and intends to make follow-on investments.

FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA.

Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Atlas Venture Life Science Advisors LLC (Atlas Venture) is a venture capital firm founded in 2014. The firm is headquartered in Cambridge, Massachusetts.

Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023.

Octagon Capital Advisor/ Private Equity (Octagon Capital) is a private equity subsidiary of Octagon Capital Advisors LP founded in 2019 by Ting Jia. The firm is headquartered in New York.

Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts.

Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California.

Septerna, Inc. is a biotechnology company located in an undisclosed location. The American company is focused on developing novel, oral small molecule drugs that target the entire class of G protein-coupled receptors (GPCRs). The company's Native Complex™ platform allows for the rapid application of new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. Septerna is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. The company was founded in 2022 by scientific founders who have made groundbreaking GPCR discoveries, including Patrick Sexton, Arthur Christopoulos, Robert Joseph Lefkowitz, and Jeffrey T. Finer. Jeffrey T. Finer has been the CEO since incorporation.

Octagon Capital Advisors LP (Octagon) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Ting Jia in 2019. Octagon provides discretionary investment advisory services to master-feeder, mini-master feeder, and Delaware series trust structures comprised of affiliated pooled investment vehicles.

HHLR Management Pte Ltd. (HHLR) is an alternative investment management firm headquartered in Singapore. The firm is a subsidiary of Hillhouse Capital Group Ltd. in Hong Kong. Formerly known as Hillhouse Capital Management Pte Ltd., HHLR provides investment solutions to institutional investors as well as to non-profit foundations.

Bluejay Therapeutics, Inc. is a clinical stage private biopharmaceutical company that is committed to developing effective treatments and cures for viral and liver diseases. The company is based in San Mateo, CA, and was founded by Keting Chu, who has been the CEO since incorporation. The company's first target indication is chronic hepatitis b, which is a worldwide prevalent disease with an urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for a high rate of functional cure: fully human igg1 anti-hbs monoclonal antibodies and first-in-class hbsag oral small molecule inhibitors. The company believes that by reducing hepatitis b surface antigen and restoring adaptive immunity, a functional cure could be achieved for patients.

SARcode Bioscience, Inc., develops biopharmaceutical products. Its program is a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists for the treatment T-cell mediated inflammatory diseases. The company was founded by Thomas Gadek and John P. Burnier in 2006 and is headquartered in Brisbane, CA.

Part of Nuvation Bio, Inc., AnHeart Therapeutics, Inc. is a clinical stage biopharmaceutical company based in New York, NY. AnHeart Therapeutics is focused on developing a pipeline of novel precision oncology therapeutics for areas of significant unmet medical need. The company's lead investigational therapy, taletrectinib, is a next-generation ROS1-inhibitor currently in pivotal phase 2 trials for ROS1-positive non-small cell lung cancer (NSCLC). AnHeart Therapeutics, Inc. also has a second investigational therapy, safusidenib, being evaluated in a phase 2 trial for -mutant glioma. AnHeart Therapeutics is supported by leading life sciences investors and has built an organization with deep oncology drug discovery and development expertise. The company was founded by Bing Yan, Junyuan Jerry Wang, Lihua Zheng, and the CEO is Junyuan Jerry Wang. AnHeart Therapeutics was acquired by Nuvation Bio, Inc. on April 09, 2024 for $89.30 million.

BVF Partners LP (BVF) is a SEC-registered investment advisor and hedge fund manager headquartered in San Francisco, California. The firm was founded in 1993 and is a subsidiary of BVF, Inc. BVF provides discretionary advisory services to private investment vehicles which includes commingled limited partnerships (the BVF Funds) and a limited liability entity organized for a single investor (Single Investor Fund) as well as to separately managed accounts.

The Drug Information Association is a non-profit multidisciplinary association that operates to promote health and well-being. The non-profit company is based in Horsham, PA. Marwan Fathallah has been the CEO of the company since 2023.

SEQUUS Pharmaceuticals, Inc. is based in Menlo Park, CA. Part of Johnson & Johnson, SEQUUS Pharmaceuticals, Inc. is a company that markets lipid-based biopharmaceutical products mainly to treat cancer and infectious diseases. SEQUUS Pharmaceuticals was acquired by ALZA Corp., part of Johnson & Johnson from June 22, 2001 on March 16, 1999 for $658.03 million.